What is the full potential of baricitinib in treating patients with COVID-19?

Kathryn Biddle^{1

2}, Jonathan White¹, Nidhi Sofat^{1

2}

Affiliations

¹ General Medicine, St George's University Hospitals NHS Foundation Trust, London, UK.
² Institute for Infection & Immunity, St George's, University of London and Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, UK.

Editorial

Kathryn Biddle et al. Expert Rev Clin Immunol. 2022 Jun.

. 2022 Jun;18(6):545-549.

doi: 10.1080/1744666X.2022.2072298. Epub 2022 May 2.

Kathryn Biddle^{1

2}, Jonathan White¹, Nidhi Sofat^{1

2}

¹ General Medicine, St George's University Hospitals NHS Foundation Trust, London, UK.
² Institute for Infection & Immunity, St George's, University of London and Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, UK.

No abstract available

Keywords: Baricitinib; COVID-19; Janus-kinase inhibitors; SARS-CoV-2; immunomodulation.

Publication types